Azaindoline Compounds as Selective Granzyme B Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Granzyme B inhibitors are either nonspecific, costly to manufacture, or present drug delivery challenges, limiting their effectiveness in treating Granzyme B-related diseases and conditions.
Innovation Solution
Development of azaindoline compounds that act as selective Granzyme B inhibitors, including specific compounds with Formulae (I), (II), and (III), which are simple to manufacture and effective in inhibiting Granzyme B activity, suitable for pharmaceutical compositions and methods of treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonspecific inhibitors such as isocoumarins are used, then Granzyme B inhibition is achieved, but specificity and potency are insufficient
Solution Approach 1:
The patent applies local quality by designing the inhibitor molecule with specific functional groups positioned at precise locations to interact with unique features of the Granzyme B active site. The compounds contain a hydroxamate group combined with specific heterocyclic moieties that form localized interactions with Granzyme B residues, providing high specificity while avoiding off-target effects on other serine proteases.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure of the inhibitor compounds, including different heterocyclic rings, substituent positions, and chain lengths. These structural parameter variations allow optimization of both potency and specificity for Granzyme B, achieving nanomolar inhibition constants while maintaining selectivity against other proteases.
2Reliability
If biological inhibitors such as serpinB9 are used, then Granzyme B inhibition is achieved, but manufacturing cost and delivery challenges increase
Solution Approach 1:
The patent applies this principle by replacing complex biological inhibitors with small molecule chemical compounds that are cheaper to manufacture. The synthetic organic compounds can be produced through established pharmaceutical chemistry methods, eliminating the need for expensive protein expression, purification, and stabilization processes required for biological inhibitors like serpinB9.
Solution Approach 2:
The patent substitutes the complex biological mechanism of serpin-based inhibition with a simpler chemical inhibition mechanism. The small molecule inhibitors directly bind to and inhibit Granzyme B through chemical interactions, replacing the need for complex protein-protein interactions and biological pathways, thereby simplifying manufacturing and delivery.
3Reliability
If tricyclic inhibitors are used, then Granzyme B inhibition is achieved, but synthetic complexity and manufacturing cost increase due to complex core structure
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a hydroxamate group for metal coordination, heterocyclic moieties for specific binding interactions, and linkers for positional flexibility. This modular segmentation simplifies the overall molecular structure compared to complex tricyclic systems while maintaining effective Granzyme B inhibition through coordinated actions of the separate segments.
Solution Approach 2:
The patent extracts and eliminates the complex tricyclic core structure from the inhibitor design, retaining only the essential functional elements required for Granzyme B inhibition. By removing unnecessary structural complexity and keeping only the active pharmacophore elements, the patent achieves simplified molecules that are easier and cheaper to manufacture while preserving inhibitory effectiveness.
Data Source
AI summary
Azaindoline compounds as granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.